Evaxion announces business update and second quarter 2025 financial results
Provided By GlobeNewswire
Last update: Aug 14, 2025
COPENHAGEN, Denmark, August 14, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces second quarter 2025 financial results.
Read more at globenewswire.com
